FDA Accepts Application for SARCLISA (Isatuximab-IRFC) by Sanofi
The FDA has accepted the Biologics License Application for SARCLISA (Isatuximab-IRFC) from Sanofi.
Published: July 15, 2026
Updated: July 15, 2026
Author: Humanexa Intelligence
Therapeutic area: Oncology / Monoclonal Antibody
Company: Sanofi
Asset: SARCLISA
Indication: multiple myeloma therapies
Regulatory TimelineREG
Fast Track
Breakthrough
Priority Review
PDUFA
Approval
Company
Sanofi
Asset
Signal assessment
Signal strength
high
Confidence level
high
Signalhigh
Confidencehigh
Why it matters
The FDA's acceptance of the BLA for SARCLISA represents a significant step for Sanofi in the competitive oncology landscape. This development could enhance their market position and necessitates close monitoring of the review timeline and approval outcomes.
Recommended action
Humanexa recommends Monitor.
Analysis
Monitor the timeline for FDA review and potential approval outcomes for SARCLISA.
Related companies & assets
Companies
Assets
Sources & Humanexa intelligence
Related Humanexa pages
Related signals
Newsletter
Get signals before the market moves
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.